nach oben

European Surgery

Erschienen in:

01.10.2015 | Original Article

The assay and clinical significance of serum thymidine kinase 1 in patients with colorectal carcinoma

verfasst von: Y. Zhang, J. Wang, J. Xie, D. Yang, G. Han, Y. Zhang, Q. Fu

Erschienen in: European Surgery | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Summary

Background

Thymidine kinase 1 was regarded as a good serological marker for cell proliferation. In recent years, the role of thymidine kinase 1 in occurrence, development, and prognosis of tumors gradually attracted people’s attention and had been regarded as a sensitive indicator of tumor. The aim of the present study was to investigate the clinical value of detection of serum thymidine kinase 1 in colorectal carcinoma.

Methods

In this study, the level of serum thymidine kinase 1 in 150 patients with colorectal carcinoma, 36 patients with benign colorectal diseases, and 40 normal controls was determined by a chemiluminescence dot blot assay.

Results

The level of serum thymidine kinase 1 in patients with colorectal carcinoma was much higher than that in patients with benign colorectal diseases and normal controls (P < 0.01), but there was no significant difference between the level of serum thymidine kinase 1 in patients with benign colorectal diseases and that in normal controls (P > 0.05). The level of serum thymidine kinase 1 declined significantly 1 month after operation. The positive rate of serum thymidine kinase 1 in patients with colorectal carcinoma was much higher than other digestive tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen (CA-199, CA-724)].

Conclusions

The detection of serum thymidine kinase 1 might have high clinical value in auxiliary diagnosis, curative effect monitoring, and prognosis judgment of colorectal carcinoma.

Vorheriger Artikel Experience of colonic J pouch reconstruction following anterior resection

Nächster Artikel Galectin-3 as a potential biomarker in colorectal cancer?

Li Z, Wang Y, He J, et al. Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas. Eur J Cancer Prev. 2010;19(4):313–8.CrossRefPubMed

Zhang F, Li H, Pendleton AR, et al. Thymidine kinase 1 immunoassay: a potential marker for breast cancer. Cancer Detect Prev. 2001;25(1):8–15.PubMed

Aufderklamm S, Todenhöfer T, Gakis G, et al. Thymidine kinase and cancer monitoring. Cancer Lett. 2012;316(1):6–10.CrossRefPubMed

Guan H, Sun Y, Zan Q, et al. Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: a useful tool in tumor therapy management. Mol Med Rep. 2009;2(6):923–9.PubMed

Xu XH, Zhang YM, Shu XH, et al. Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy. Mol Med Rep. 2008;1(5):705–11.PubMed

Wu BJ, Li WP, Qian C, Ding W, Zhou ZW, Jiang H. Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma. Tumour Biol. 2013;34(2):643–8.CrossRefPubMed

Bolayirli M, Papila C, Korkmaz GG, et al. Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy. J Clin Lab Anal. 2013;27(3):220–6.CrossRefPubMed

Luo P, He E, Eriksson S, et al. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker. Eur J Cancer Prev. 2009;18(3):220–4.CrossRefPubMed

Zhou J, He E, Skog S. The proliferation marker thymidine kinase 1 in clinical use. Mol Clin Oncol. 2013;1(1):18–28.PubMedCentralPubMed

10.

He Q, Mao Y, Wu J, et al. Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int J Oncol. 2004;25(4):945–53.PubMed

11.

Lee SJ, Lee HJ, Moon DH. Quantitative analysis of thymidine kinase 1 and 5′(3′)-deoxyribonucleotidase mRNA expression: the role of fluorothymidine uptake. Anticancer Res. 2011;31(6):2135–9.PubMed

12.

Xiang Y, Zeng H, Liu X, et al. Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: a meta‑analysis. Biomed Rep. 2013;1(4):629–37.PubMedCentralPubMed

13.

Chen G, He C, Li L, et al. Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix. BMC Cancer. 2013;13:249.PubMedCentralCrossRefPubMed

14.

Chen F, Tang L, Xia T, et al. Serum thymidine kinase 1 levels predict cancer‑free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer. Mol Clin Oncol. 2013;1(5):894–902.PubMedCentralPubMed

15.

Karbownik M, Brzezianska E, Lewinski A. Increased expression of mRNA specific for thymidine kinase, deoxycytidine kinase or thymidine phosphorylase in human papillary thyroid carcinoma. Cancer Lett. 2005;225(2):267–73.CrossRefPubMed

16.

Faria M, Halquist MS, Kindt E, Li W, Karnes HT, O’Brien PJ. Liquid chromatography–tandem mass spectrometry method for quantification of thymidine kinase activity in human serum by monitoring the conversion of 3-deoxy-3-fluorothymidine to 3-deoxy-3-fluorothymidine monophosphate. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;907:13–20.CrossRefPubMed

17.

Bjöhle J, Bergqvist J, Gronowitz JS, et al. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial. Breast Cancer ResTreat. 2013;139(3):751–8.CrossRef

18.

Hannigan BM, Barnett YA, Armstrong DB, McKelvey-Martin VJ, McKenna PG. Thymidine kinases: the enzymes and their clinical usefulness. Cancer Biother. 1993;8(3):189–97.CrossRefPubMed

19.

Xu Y, Shi QL, Ma H, et al. High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma. Tumour Biol. 2012;33(2):475–83.CrossRefPubMed

20.

Nisman B, Yutkin V, Nechushtan H, et al. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. Urology. 2010;76(2):513.e1–6.CrossRef

21.

Korkmaz T, Seber S, Okutur K, et al. Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer. Biomarkers. 2013;18(1):88–94.CrossRefPubMed

22.

He Q, Skog S, Wang N, Eriksson S, Tribukait B. Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Eur J Cell Biol. 1996;70(2):117–24.PubMed

23.

Huang S, Lin J, Guo N, et al. Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression. Asian Pac J Cancer Prev. 2011;12(2):497–505.PubMed

24.

Alegre MM, Weyant MJ, Bennett DT, et al. Serum detection of thymidine kinase 1 as a means of early detection of lung cancer. Anticancer Res. 2014;34(5):2145–51.PubMed

25.

Procházka V, Faber E, Raida L, Langová K, Indrák K, Papajík T. High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma. Leuk Lymphoma. 2012;53(7):1306–10.CrossRefPubMed

26.

Chen ZH, Huang SQ, Wang Y, et al. Serological thymidine kinase 1 is a biomarker for early detection of tumours—a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay. Sensors (Basel). 2011;11(12):11064–80.CrossRef

27.

Nisman B, Allweis T, Kaduri L, et al. Serum thymidine kinase 1 activity in breast cancer. Cancer Biomark. 2010;7(2):65–72.PubMed

28.

Pan ZL, Ji XY, Shi YM, Zhou J, He E, Skog S. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients. J Cancer Res Clin Oncol. 2010;136(8):1193–9.CrossRefPubMed

29.

Alegre MM, Robison RA, O’Neill KL. Thymidine kinase 1 upregulation is an early event in breast tumor formation. J Oncol. 2012;2012:575647.PubMedCentralCrossRefPubMed

30.

Huang ZH, Tian XS, Li R, et al. Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer. Exp Ther Med. 2012;3(2):331–5.PubMedCentralPubMed

31.

Li HX, Lei DS, Wang XQ, Skog S, He Q. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol Rep. 2005;13(1):145–9.PubMed

32.

Zhang J, Jia Q, Zou S, et al. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical out-come of primary bladder carcinoma patients. Oncol Rep. 2006;15(2):455–61.PubMed

Titel: The assay and clinical significance of serum thymidine kinase 1 in patients with colorectal carcinoma
verfasst von: Y. Zhang
J. Wang
J. Xie
D. Yang
G. Han
Y. Zhang
Q. Fu
Publikationsdatum: 01.10.2015
Verlag: Springer Vienna
Erschienen in: European Surgery / Ausgabe 5/2015
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI: https://doi.org/10.1007/s10353-015-0342-8

Springer Medizin Österreich

Summary

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Hand-assisted laparoscopic surgery for left sided colorectal cancer: is quality of surgery related with experience?

Surgery, limos and shine keep things going

The complex interplay between Notch signaling and Snail1 transcription factor in the regulation of epithelial–mesenchymal transition (EMT)

Galectin-3 as a potential biomarker in colorectal cancer?

Retroperitoneal necrotizing fasciitis secondary to Fournier’s gangrene

Transanal endoscopic microsurgery in treatment of small rectal T1 high-risk, T2 and T3 carcinomas combined with radiochemotherapy